ライフサイエンスコーパス: acetazolamide

1 30% IOP reduction and no pain (without oral acetazolamide).

2 Hg and an IOP reduction of 30% (without oral acetazolamide).

3 relate to the reported beneficial effects of acetazolamide.

4 carbonic anhydrase (CA) inhibitors, such as acetazolamide.

5 ree-fold by the carbonic anhydrase inhibitor acetazolamide.

6 lpha-CA deletion mutant and the CA inhibitor acetazolamide.

7 symmetric blood flow and normal response to acetazolamide.

8 edly low blood flow and abnormal response to acetazolamide.

9 c paralysis and the patient's worsening from acetazolamide.

10 ding pilocarpine, epinephrine compounds, and acetazolamide.

11 is formation is increased in the presence of acetazolamide.

12 ertigo and ataxia that are not responsive to acetazolamide.

13 (n = 7) was injected intravenously with 1 g acetazolamide.

14 te levels alter the decongestive response to acetazolamide.

15 rzolamide and an additional 5 months of oral acetazolamide.

16 to 12.56; P < .001) were also observed with acetazolamide.

17 f interaction between carbonic anhydrase and acetazolamide.

18 s of dilation despite pretreatment with oral acetazolamide.

19 ne order of magnitude better than the parent acetazolamide 1 were also identified in this study, toge

20 The mean improvement in PMD was greater with acetazolamide (1.43 dB, from -3.53 dB at baseline to -2.

21 Mean improvements in papilledema grade (acetazolamide: -1.31, from 2.76 to 1.45; placebo: -0.61,

22 In addition, under the conditions used here, acetazolamide (100 microM) did not have a significant ef

23 lication of the carbonic anhydrase inhibitor acetazolamide (100 microM) in the presence of CO2/HCO3-

24 occurred in 59% of rats receiving high-dose acetazolamide (200 mg/kg).

25 rats (n = 100) were randomized to either IP acetazolamide, 200 mg/kg (high-dose), or IP saline twice

26 Acetazolamide (222 g/mol) binding to carbonic anhydrase

27 The acetazolamide (3.6 mum) and placebo (2.1 mum) groups sho

28 but was reversed by reacidifying the blood (acetazolamide; 3% FiCO2).

29 d by acetazolamide (day 3: placebo 74.8% vs. acetazolamide 41.3%, P < 0.001).

30 Low-dose acetazolamide (50 mg/kg) produced a pH (7.22 +/- 0.07) t

31 Acetazolamide (50 microM) doubled the size of the dendri

32 of acidosis induced by intraperitoneal (IP) acetazolamide (50 or 200 mg/kg) or saline.

33 n rats (n = 75) were randomized to either IP acetazolamide, 50 mg/kg (low-dose), or IP saline twice d

34 per milliliter to receive either intravenous acetazolamide (500 mg once daily) or placebo added to st

35 c peptide) >250 ng/mL to receive intravenous acetazolamide (500 mg once daily) or placebo in addition

36 Acetazolamide (500 mg twice daily) was administered for

37 olume overload in a 1:1 ratio to intravenous acetazolamide (500 mg/day) or matching placebo on top of

38 Dorzolamide and acetazolamide (500 microM) did not show additive inhibit

39 Acetazolamide (500-1000 mg, twice daily) vs placebo admi

40 - 1-2.3 +/- 1; P = 0.02) and the use of oral acetazolamide (61%-11%; P < 0.01) were also reduced.

41 termine the effects of three dosages of oral acetazolamide (62.5, 125, and 250 mg, all twice daily) i

42 mide also experienced a reduction in weight (acetazolamide: -7.50 kg, from 107.72 kg to 100.22 kg; pl

43 At altitude, patients either took acetazolamide (750 mg/d) or placebo in addition to autoC

44 asured by the National Eye Institute VFQ-25 (acetazolamide: 8.33, from 82.97 to 91.30; placebo: 1.98,

45 and its 10-item neuro-ophthalmic supplement (acetazolamide: 9.82, from 75.45 to 85.27; placebo: 1.59,

46 to have previous treatment with an oral CAI (acetazolamide), a topical CAI (brinzolamide/dorzolamide)

47 We found that systemic administration of acetazolamide, a CA inhibitor, immediately after the ext

48 f motor coordination that was ameliorated by acetazolamide, a carbonic anhydrase inhibitor that minim

49 Whether acetazolamide, a carbonic anhydrase inhibitor that reduc

50 c-PHC-102 is a (99m)Tc-labeled derivative of acetazolamide, a high-affinity small organic ligand of c

51 Acetazolamide, a membrane-permeable CA inhibitor, was us

52 Acetazolamide, a proximal tubule diuretic, delivers more

53 in this study, consisting of a derivative of acetazolamide, a spacer, and a peptidic (99m)Tc chelator

54 drase isoforms I, II, IX, XII, and XIV using acetazolamide (AAZ) as reference compound.

55 Infusion of acetazolamide abolished the positive PD in the later seg

56 in the presence and absence of HCO(3)(-) and acetazolamide (ACTZ) using tissue treated with siRNA spe

57 substance associated with doping in sports: acetazolamide (ACTZ).

58 h and without niflumic acid (MCT inhibitor), acetazolamide (ACTZ, a CA inhibitor), 5-(N-Ethyl-N-isopr

59 determine whether the beneficial effects of acetazolamide (ACZ) in improving vision at 6 months cont

60 Acetazolamide (ACZ) is used to prevent acute mountain si

61 Administration-approved small-molecule drug acetazolamide (ACZ).

62 al trial, study eyes of subjects assigned to acetazolamide (ACZ, n = 44) or placebo (PLB, n = 43) had

63 owing metabolic acidosis (via 2 days of oral acetazolamide; ACZ) with and without acute restoration o

64 obstructive sleep apnoea (OSA).However, how acetazolamide affects the key traits causing OSA remains

65 show that SLC-149 is a better inhibitor than acetazolamide against CAIX.

66 F); others were treated with weight loss and acetazolamide alone.

67 She was first treated by intravenous 250 mg acetazolamide along with maximal pressure-lowering drops

68 Participants assigned to acetazolamide also experienced a reduction in weight (ac

69 reasing distal volume delivery elicited with acetazolamide also led to increases in renal interstitia

70 ha-CA knockout mutant and in the presence of acetazolamide, although UreI and urease remained fully f

71 ated HCO(3)(-) secretion was not affected by acetazolamide, an inhibitor of carbonic anhydrase.

72 he high-power LFOs are decreased markedly by acetazolamide and 4-aminopyridine, the primary treatment

73 Acetazolamide and autoCPAP resulted in better control of

74 derately elevated altitude, a combination of acetazolamide and autoCPAP therapy, compared with autoCP

75 Acetazolamide and autoCPAP treatment was associated with

76 Both acetazolamide and DIDS reduced chloride effluxes.

77 Treatment of algae with the CA inhibitors acetazolamide and ethoxyzolamide decreased photosyntheti

78 e 33-fold lower than reference drugs such as acetazolamide and gabapentin.

79 Acetazolamide and glucose infusion resulted in a negativ

80 /- 0.4 ms, S.E., n = 11 mice) and blocked by acetazolamide and increasing external pH (to decrease CO

81 Inhibition of total CA activity with acetazolamide and inhibition of extracellular-facing mem

82 The carbonic anhydrase (CA) inhibitors acetazolamide and its structurally similar analogue meth

83 avoided, and proximally acting agents (e.g., acetazolamide and loop diuretic agents) are preferred.

84 the right eye even under treatment with oral acetazolamide and maximal tolerated doses of topical ant

85 free conditions, DIDS, and the CA inhibitors acetazolamide and methazolamide but not by the Na-H exch

86 ated with cGMP production and is enhanced by acetazolamide and raloxifene.

87 rong inhibition of hCA IX/XII, outperforming acetazolamide and SLC-0111.

88 ngestion of the carbonic anhydrase inhibitor acetazolamide and the ion exchange inhibitor DIDS (4,4'-

89 hdrawal, to the carbonic anhydrase inhibitor acetazolamide and to H2DIDS inhibition.

90 observed between the effect of allocation to acetazolamide and UNa on decongestion (P = 0.007).

91 In IIH, acetazolamide and weight loss effectively improve RNFL t

92 eated with anticoagulation and 100% required acetazolamide and/or lumbar puncture.

93 t additive to unselective CA inhibition with acetazolamide, and independent of extracellular potassiu

94 Whether the beneficial effects of acetazolamide are consistent across the entire range of

95 lowing metabolic acidosis via 2 days of oral acetazolamide at 250 mg every 8 h (ACZ; pH: -0.07 0.04 a

96 ce interval (CI), 1.03-3.79) and use of oral acetazolamide at baseline (HR, 1.74; 95% CI, 1.13-2.70),

97 Asian ethnicity and use of oral acetazolamide at baseline were associated with greater f

98 Finally, the blockade of water entry by acetazolamide attenuated ballooning in vitro and markedl

99 contributes to lithium-NDI development, and acetazolamide attenuates lithium-NDI development in mice

100 arbonic buffer was increased again by adding acetazolamide (ATZ), a membrane permeant carbonic anhydr

101 wed by the carbonic anhydrase (CA) inhibitor acetazolamide (ATZ).

102 Acetazolamide-augmented blood oxygenation level-dependen

103 ased computational framework for analysis of acetazolamide-augmented BOLD imaging can be used to meas

104 hronic steno-occlusive disease who underwent acetazolamide-augmented BOLD imaging for recurrent minor

105 emonstrate comprehensive characterization of acetazolamide-augmented BOLD MRI response in chronic ste

106 luorescent derivative of the CA IX inhibitor acetazolamide (AZ).

107 se IX (CAIX) overexpression and inhibited by acetazolamide (AZA) administration.

108 rbonic anhydrase II (CaII) and its inhibitor acetazolamide (AZM) into E. coli cell lysate as a model

109 The clinically used acetazolamide (AZM) is a sulfonamide that binds with hig

110 c carbonic anhydrase (CA) inhibitors with an acetazolamide backbone.

111 l, we demonstrate a successful example of an acetazolamide-based lead compound with in vivo therapeut

112 ith AE2, these latter two being sensitive to acetazolamide because of their association with the cyto

113 e assessed the uptake of 10 pharmaceuticals (acetazolamide, beclomethasone, carbamazepine, diclofenac

114 failure, administration of a single dose of acetazolamide before sleep improves central sleep apnea

115 x with five CA sulfonamide-based inhibitors (acetazolamide, benzolamide, chlorzolamide, ethoxzolamide

116 Variability in the quality of the acetazolamide binding responses was likely a product of

117 Although we detected acetazolamide binding to immobilized CA II and specific

118 Our findings suggest that acetazolamide can improve OSA, probably due to reduction

119 pe 1 diabetes and preserved kidney function, acetazolamide caused an acute, reversible reduction in m

120 sessment of cerebrovascular reserve by using acetazolamide challenge in patients with intracranial va

121 tric blood flow and abnormal response to the acetazolamide challenge test may require a revasculariza

122 mography (CT) in the resting state and after acetazolamide challenge.

123 on and apoptosis in PC12 cells; and (3) that acetazolamide, chlorthalidone, and the neurosteroid, all

124 invasive mechanical ventilation, the use of acetazolamide, compared with placebo, did not result in

125 Acetazolamide completely blocked the increase in Cl(-)/H

126 CA XIV at 2.8 A resolution and of an enzyme-acetazolamide complex at 2.9 A resolution.

127 "130's segment." The structure of the CA XII-acetazolamide complex is also reported at 1.50-A resolut

128 Additionally, the structure of the acetazolamide complex is essentially identical to that o

129 groups onto the par excellence CA inhibitor acetazolamide, compounds that may interact with the dist

130 The acetazolamide conjugate described in this study could be

131 The (99m)Tc-labeled acetazolamide conjugate exhibits high tumor uptake and f

132 erties of said ligand and understand whether acetazolamide conjugates merit further development as dr

133 Acetazolamide consistently increased the likelihood of d

134 The effects of acetazolamide could be mimicked by either amiloride or b

135 The effects of acetazolamide could be mimicked by removal of HCO3-/CO2

136 y questions remain regarding the efficacy of acetazolamide, CSF shunting procedures and cerebral tran

137 g the treatment phase which was prevented by acetazolamide (day 3: placebo 74.8% vs. acetazolamide 41

138 We have previously described a novel acetazolamide derivative, a carbonic anhydrase ligand wi

139 Acetazolamide did not affect the cotransport stoichiomet

140 unclear whether the decongestive effects of acetazolamide differ across the spectrum of left ventric

141 We conclude that acetazolamide does not function as either a nitrous anhy

142 ups 72 hrs after administration of the first acetazolamide dose (31.8 +/- 4.9-25.3 +/- 3.8 mEq/L, p <

143 Acetazolamide dose was lower in bariatric patients, star

144 inhaled sodium nitrite were not increased by acetazolamide during alveolar hypoxia.

145 The efficacy and safety of an acetazolamide-eluting biodegradable tubular stent (AZ-BT

146 atients with symmetric blood flow and normal acetazolamide-enhanced challenge test results will do we

147 nic anhydrase inhibitor (CAI); however, CAIs acetazolamide, ethoxyzolamide, dichlorphenamide, chlorth

148 inically used carbonic anhydrase inhibitors, acetazolamide, ethoxzolamide, and dorzolamide, have prom

149 r inhibitors, among which are methazolamide, acetazolamide, ethoxzolamide, dorzolamide, brinzolamide,

150 Acetazolamide facilitates decongestion in acute decompen

151 Simultaneous administration of acetazolamide fully prevented the procognitive effects o

152 For the acetazolamide group (n = 187), compared with the placebo

153 ccurred in 76 of 256 patients (29.7%) in the acetazolamide group and in 72 of 259 patients (27.8%) in

154 curred in 108 of 256 patients (42.2%) in the acetazolamide group and in 79 of 259 (30.5%) in the plac

155 At 6 months, the acetazolamide group had greater reduction than the place

156 < .001) decreased significantly more in the acetazolamide group.

157 potency series of thiazide diuretic action (acetazolamide > chlorothiazide > metolazone) differed si

158 However, only acetazolamide has been explored for in vivo efficacy in

159 An inhibitor of CAs, acetazolamide has been reported to inhibit invasion.

160 The carbonic anhydrase inhibitor acetazolamide has been used as a treatment for hypokalae

161 Acetazolamide has been used for decades as a respiratory

162 With the addition of acetazolamide, however, acid-base balance as well as ENa

163 roup previously showed the 1,3,4-thiadiazole acetazolamide human carbonic anhydrase inhibitor scaffol

164 d a higher proportional treatment effect for acetazolamide if baseline HCO3 >= 27 mmol/l.

165 Moreover, systemic administration of acetazolamide immediately after the extinction training

166 reas d-phenylalanine potentiated extinction, acetazolamide impaired extinction also when infused loca

167 In the ADVOR trial, acetazolamide improved decongestion in acute decompensat

168 Randomization towards acetazolamide improved decongestive response over the en

169 Acetazolamide improved prothrombin time, factor X, and a

170 Acetazolamide improved subjective perception of overall

171 Acetazolamide improves decongestive response over the en

172 ics in patients with acute decompensated HF, acetazolamide improves the incidence of successful decon

173 , double-masked, placebo-controlled study of acetazolamide in 165 participants with IIH and mild visu

174 ngly related to successful decongestion with acetazolamide in ADHF.

175 mented NO generation by CA from nitrite with acetazolamide in anaesthetized pigs during alveolar hypo

176 (Acetazolamide in Decompensated Heart Failure with Volume

177 tion and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume

178 Patients from the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume

179 ludes all 519 patients from the ADVOR trial (Acetazolamide in Decompensated Heart Failure With Volume

180 tested the effect of the CA-specific blocker acetazolamide in lithium-NDI.

181 inical outcomes and decongestive response to acetazolamide in patients with acute decompensated heart

182 Trial (IIHTT) reported beneficial effects of acetazolamide in patients with mild visual loss.

183 The kidney effects and safety of acetazolamide in persons with type 1 diabetes have not b

184 Acetazolamide in Persons with Type 1 Diabetes, NCT054733

185 scans show more extensive hypoperfusion than acetazolamide in the two cases.

186 Acetazolamide increased the odds of successful decongest

187 Acidosis induced by high-dose acetazolamide, independent of hyperoxemia or hypoxemia,

188 Studies in mice treated with acetazolamide indicated that increased bicarbonate and f

189 study, the following hypothesis was tested: acetazolamide-induced acidosis is associated with preret

190 It can be assessed by measuring the acetazolamide-induced change in regional cerebral blood

191 Acetazolamide induces a metabolic acidosis via an altern

192 Carbonic anhydrase (CA) inhibitors such as acetazolamide inhibit hypoxic pulmonary vasoconstriction

193 Acetazolamide inhibited the carbonic anhydrase activity

194 Acetazolamide inhibited the short-circuit current throug

195 Acetazolamide inhibits proximal tubular sodium and bicar

196 Acetazolamide inhibits proximal tubular sodium reabsorpt

197 increased more after dipyridamole than after acetazolamide injection in two patients.

198 However, current measurement methods require acetazolamide injection or hypercapnia challenge, prompt

199 Acetazolamide is a mild diuretic and a respiratory stimu

200 Acetazolamide is associated with a higher rate of succes

201 Acetazolamide is commonly used to treat idiopathic intra

202 AZATAX was designed to establish whether acetazolamide is safe and improves cerebellar syndrome i

203 Acetazolamide is well tolerated and effective for motor

204 in complex with a nonspecific CA inhibitor, acetazolamide, is available in Protein Data Bank.

205 species, reducing aqueous humor inflow with acetazolamide lowered IOP and administering water intrap

206 There is some evidence to suggest that acetazolamide may improve obstructive sleep apnoea (OSA)

207 al of HCO(3)(-)/CO(2) was inhibited by DIDS, acetazolamide, methazolamide, and low-chloride buffer.

208 Furosemide but not acetazolamide (n = 6 each) increased medullary oxygenati

209 0.06, P < 0.001); however, neither low-dose acetazolamide nor saline induced preretinal neovasculari

210 examine the prolonged duration of action of acetazolamide observed in this study as well as the effe

211 erved in this study as well as the effect of acetazolamide on clinical end points, such as duration o

212 ween serum chloride levels and the effect of acetazolamide on death or heart failure readmissions was

213 is study sought to investigate the effect of acetazolamide on natriuresis in ADHF and its relationshi

214 We aimed to investigate the effect of acetazolamide on the traits contributing to OSA and its

215 zed to receive intravenous administration of acetazolamide, one dose of 500 mg or 250 mg every 6 hrs

216 dependent chloride/bicarbonate exchange with acetazolamide or chlorthalidone.

217 No effects were observed when acetazolamide or d-phenylalanine was infused locally int

218 lated by 7,8-benzoquinoline and inhibited by acetazolamide or HCO3-/CO2 removal can be said to repres

219 omized 519 patients with ADHF to intravenous acetazolamide or matching placebo on top of intravenous

220 Volume Overload), randomized to intravenous acetazolamide or matching placebo on top of intravenous

221 n 18 to 55 years of age with IIH were taking acetazolamide or methazolamide in 2018 (6828 / 0.25 = 27

222 age with IIH diagnoses and prescriptions for acetazolamide or methazolamide in 2018 were identified,

223 iaries with IIH, 6828 had a prescription for acetazolamide or methazolamide.

224 This effect is not blocked by acetazolamide or MK-801, indicating that permeability of

225 structures of CrCAH3 in complex with either acetazolamide or phosphate ions were determined at 2.6-

226 ion for more 24 hours were randomized to the acetazolamide or placebo group and 380 were included in

227 d to a double-blind cross-over protocol with acetazolamide or placebo, taken 1 h before bedtime for s

228 CO(2) did not change after administration of acetazolamide or progesterone.

229 Treatment of lithium-NDI mice with acetazolamide or thiazide/amiloride induced similar anti

230 tic agents (loop diuretic agents, thiazides, acetazolamide) or mechanical devices.

231 al dorzolamide, oral dosing of eplerenone or acetazolamide, or some combination thereof.

232 y dilation was enhanced by administration of acetazolamide (oral or intra-arterial) and oral raloxife

233 s intermediate between high-dose (200 mg/kg) acetazolamide (P < 0.001) and saline controls (7.42 +/-

234 chloride, which was effectively prevented by acetazolamide (P<0.001).

235 o-plus-diet or maximally tolerated dosage of acetazolamide-plus-diet.

236 We found that acetazolamide prevents HPV in anaesthetized pigs, as in

237 3 exhibited a significant higher response to acetazolamide [primary endpoint: no vs. elevated HCO3; O

238 A total of 17 patients received oral acetazolamide prior to surgery to acutely lower IOP.

239 High-dose acetazolamide produced a severe acidosis (pH 7.13 +/- 0.

240 pupillary dilation with tropicamide and oral acetazolamide prophylaxis.

241 and analyzed an identical dilution series of acetazolamide (ranging from 4.1 to 1000 nM).

242 In the intact eye, DIDS and acetazolamide reduced AH secretion by 25% and 44%, respe

243 d mice with the carbonic anhydrase inhibitor acetazolamide reduced lung inflammatory pathology withou

244 Acetazolamide reduced measured GFR by 15% (95% confidenc

245 Preblocking with acetazolamide reduced more than 80% uptake of (18)F-AmBF

246 In collecting duct (mpkCCD) cells, acetazolamide reduced the cellular lithium content and a

247 Acetazolamide reduced the median [interquartile range] L

248 Preventive use of acetazolamide reduced the relative risk of SHAI by 44%.

249 Acetazolamide reduces HPV in pigs without evidence of an

250 s of complexes of HpalphaCA with a family of acetazolamide-related sulfonamides have been determined.

251 ixty-seven per cent of patients treated with acetazolamide reported a good neuromuscular response.

252 Acetazolamide resulted in improved diuretic response mea

253 We conclude that a single 500-mg dose of acetazolamide reverses nonchloride responsive metabolic

254 Low-dose acetazolamide reversibly lowered GFR in persons with typ

255 Diffusion coefficients are obtained for acetazolamide, riboflavin, sodium fluorescein, and theop

256 ng of contraction alkalosis (eg, addition of acetazolamide), second agent with alternate mechanism of

257 igh selectivity against CA II (605-fold than acetazolamide selectivity).

258 theless, purified CanB (a dimeric, anion and acetazolamide sensitive, zinc-containing type II beta-cl

259 An acetazolamide stress SPECT image was also obtained in tw

260 Allocation to acetazolamide strongly and independently predicted natri

261 In comparing placebo with acetazolamide, the hourly number of episodes of central

262 patients, with a 6-month first-phase single acetazolamide therapy group, followed by a randomized 5-

263 Add-on acetazolamide therapy improves decongestion across the e

264 n mutations in the CaV2.1 channel, for which acetazolamide therapy is suggested.

265 In the mutant or in the presence of acetazolamide, there was an approximately 3 log10 decrea

266 nderlie the reduced urinary PGE2 levels with acetazolamide, thereby contributing to the attenuation o

267 While WRF occurred more frequently with acetazolamide, this was not associated with adverse clin

268 Drugs that decrease inflow (acetazolamide, timolol) or increase outflow facility (pi

269 urple (MFCP) was tested in mice treated with acetazolamide to cause urinary alkalinization, and Ceren

270 sed the FDA-approved carbonic anhydrase drug acetazolamide to design potent antienterococcal agents.

271 duct, or gave aldosterone and NaHCO(3) plus acetazolamide to increase luminal HCO(3)(-) concentratio

272 The addition of acetazolamide to loop diuretic therapy in patients with

273 n the overall beneficial treatment effect of acetazolamide to the primary end point of successful dec

274 st clinical VRE strains from MIC = 2 mug/mL (acetazolamide) to MIC = 0.007 mug/mL (22) and 1 mug/mL (

275 In vivo, the bladders of acetazolamide-treated mice exhibited a wavelength-depend

276 s previously observed in patients but not in acetazolamide-treated mice in this study.

277 -1)) 0.37 +/- 0.04 (control), 0.16 +/- 0.03 (acetazolamide-treated), and 1.14 +/- 0.15 (forskolin-tre

278 Only the latter group showed a significant acetazolamide treatment effect.

279 Furthermore, acetazolamide treatment reduced inulin clearance and cor

280 Acetazolamide treatment was associated with higher cumul

281 diet plus the maximally tolerated dosage of acetazolamide (up to 4 g/d) or matching placebo for 6 mo

282 Analysis was stratified according to acetazolamide use.

283 trial end points and the treatment effect of acetazolamide was assessed, as was the evolution of seru

284 eline HCO3 levels on the treatment effect of acetazolamide was assessed.

285 Acetazolamide was associated with a higher incidence of

286 stent with this hypothesis, the CA inhibitor acetazolamide was found to be a strong inhibitor of gluc

287 A dose of oral acetazolamide was given before the patient left the clin

288 hese results show that the antidiuresis with acetazolamide was partially caused by a tubular-glomerul

289 21 [109.5]; IC [IC05]: 7.344 [4.591]), while acetazolamide was the second strongest (n = 51; PRR: 113

290 he use of oral glaucoma medications, such as acetazolamide, was considered a failure.

291 In the BNP-driven group, furosemide and acetazolamide were given more often and in higher doses

292 drase II and the resulting binding signal of acetazolamide were increased by a factor of 5 compared t

293 Low doses of acetazolamide were well tolerated in persons with type 1

294 Acetazolamide, which acidifies the subretinal space, had

295 lated by 7,8-benzoquinoline was sensitive to acetazolamide, which caused up to 50 % inhibition of the

296 antly associated with cancer risk, including acetazolamide, which was associated with reduced colorec

297 ts with IIH and mild visual loss, the use of acetazolamide with a low-sodium weight-reduction diet co

298 NO formation; however; combined infusion of acetazolamide with sodium nitrite inhalation did not fur

299 l, natriuresis and diuresis were higher with acetazolamide, with a higher treatment effect for patien

300 ibited by the sulfonamides ethoxzolamide and acetazolamide, yielding the lowest Ki values measured by